Pneumonia | Unilateral | Bilateral | p-value |
---|---|---|---|
Number (%) | 46 (26.7) | 126 (73.3) | |
Pneumonia onset, mean (SD), days | 8.2 (5.1) | 7.7 (3.7) | 0.47 |
Sociodemographic variables | |||
Age, mean (SD), years | 53.7 (16.6) | 63.0 (16.6) | |
Sex, n (%) | |||
Female | 28 (60.9) | 59 (46.8) | 0.10 |
Male | 18 (39.1) | 67 (53.2) | 0.10 |
Comorbidities | |||
Cardiovascular risk factor | |||
Smoke habit, n (%) | 4 (8.7) | 9 (7.1) | 0.38 |
BMI ≥ 25 kg/m2, n (%) | 20 (43.5) | 70 (55.6) | 0.25 |
Hypertension, n (%) | 16 (34.8) | 67 (53.2) | 0.033 |
type 2 Diabetes, n (%) | 4 (8.7) | 29 (23.0) | 0.035 |
Dyslipidemia, n (%) | 15 (32.6) | 53 (42.1) | 0.26 |
Respiratory diseases | |||
Asthma, n (%) | 4 (8.7) | 17 (13.5) | 0.40 |
COPD, n (%) | 3 (6.5) | 6 (4.8) | 0.65 |
Cardiovascular diseases | |||
Ischaemic heart diseases, n (%) | 1 (2.2) | 8 (6.3) | 0.28 |
Arrhythmias, n (%) | 1 (2.2) | 9 (7.1) | 0.22 |
Heart failure, n (%) | 2 (4.3) | 5 (4.0) | 0.91 |
Other diseases | |||
Chronic kidney diseases, n (%) | 0 (0.0) | 12 (9.5) | 0.030 |
Cognitive impairment, n (%) | 3 (6.5) | 7 (5.6) | 0.81 |
Cancer, n (%) | 1 (2.2) | 9 (7.1) | 0.22 |
Rheumatological diseases, n (%) | 2 (4.3) | 12 (9.5) | 0.27 |
Chronic treatment | |||
no drugs, n (%) | 8 (17.4) | 25 (19.8) | 0.60 |
1–4 drugs, n (%) | 21 (45.7) | 47 (37.3) | |
5–9 drugs, n (%) | 12 (26.1) | 31 (24.6) | |
≥ 10 drugs, n (%) | 5 (10.9) | 23 (18.3) | |
Antithrombotic/anticoagulant treatment | |||
Antithrombotic drug, n (%) | 1 (2.2) | 13 (10.3) | 0.22 |
Anticoagulant drug, n (%) | 2 (4.3) | 6 (4.8) | |
Non consumption, n (%) | 43 (93.5) | 107 (84.9) | |
Symptoms | |||
Fever, n (%) | 38 (82.6) | 106 (84.1) | 0.81 |
Cough, n (%) | 37 (80.4) | 103 (81.7) | 0.84 |
Dyspnea, n (%) | 24 (52.2) | 79 (62.7) | 0.21 |
Gastrointestinal disturbances, n(%) | 18 (39.1) | 54(42.9) | 0.66 |
Myalgias, n (%) | 17 (37.0) | 34 (27.0) | 0.20 |
Thoracic Pain, n (%) | 10 (21.7) | 17 (13.5) | 0.19 |
Pleural chest Pain, n (%) | 6 (13.0) | 4 (3.2) | 0.014 |
Rhinitis, n (%) | 4 (8.7) | 4 (3.2) | 0.13 |
Odynophagia, n (%) | 7 (15.2) | 13 (10.3) | 0.37 |
Asthenia, n (%) | 12 (26.1) | 35 (27.8) | 0.83 |
Headache, n (%) | 12 (26.1) | 35 (27.8) | 0.83 |
Dysgeusia, n (%) | 3 (6.5) | 6 (4.8) | 0.65 |
Anosmia, n (%) | 1 (2.2) | 1 (0.8) | 0.45 |
Symptoms categorized | |||
1–3 total symptoms, n (%) | 25 (54.3) | 72 (57.6) | 0.70 |
≥ 4 total symptoms, n (%) | 21 (45.7) | 53 (42.4) | |
Physical examination | |||
Temperature, mean (SD), ºC | 37.2 (0.8) | 37.3 (0.8) | 0.86 |
Heart rate, mean (SD), bpm | 96.2 (15.1) | 92.2 (16.4) | 0.20 |
Respiratory rate, median (IQR), rpm | 16.0 (14.0, 16.0) | 17.0 (15.0, 22.0) | 0.073 |
Pulse oximetry, median (IQR), % | 96.0 (94.0, 97.0) | 94.0 (91.0, 96.0) | < 0.001 |
Normal lung auscultation, n (%) | 16 (34.8) | 22 (17.5) | 0.014 |
Abnormal lung auscultation, n (%) | 8 (17.4) | 46 (36.5) | 0.014 |
Blood test | |||
CRP, median (IQR), mg/L | 29.6 (5.0, 81.5) | 81.5 (46.2, 143.0) | < 0.001 |
Lymphocytes, median (IQR), 10e3/ml | 1400.0 (1100.0, 1880.0) | 1000.0 (800.0, 1400.0) | < 0.001 |
D-Dimer, median (IQR), μg/L | 339.0 (197.0, 464.0) | 520.0 (320.0, 1030.0) | 0.035 |
Fibrinogen ≥ 500, n (%), mg/dL | 24 (52.2) | 103 (81.7) | < 0.001 |
Ferritin, median (IQR), μg/L | 618.0 (280.5, 919.0) | 424.0 (200.0, 1215.0) | 0.96 |
RT-PCR SARS-CoV-2 | |||
Negative, n (%) | 17 (37.0) | 19 (15.1) | 0.006 |
Positive, n (%) | 25 (54.3) | 97 (77.0) | |
Complications | |||
Hospital admission, n (%) | 20 (43.5) | 120 (95.2) | < 0.001 |
Pulmonary thromboembolism, n (%) | 0 (0.0) | 7 (5.6) | 0.10 |
Death, n (%) | 1 (2.2) | 10 (7.9) | 0.17 |